Molecular Modeling Approaches for the Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes
暂无分享,去创建一个
[1] Jan Williams. SciFinder from CAS: information at the desktop for scientists , 1995 .
[2] Scott L Cockroft,et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[3] Kiyomi Ito,et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.
[4] Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[5] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[6] J. Miners,et al. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. , 2006, British journal of clinical pharmacology.
[7] Y. Sugiyama,et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.
[8] J. Miners,et al. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate , 2006, European Journal of Clinical Pharmacology.
[9] Y. Sugiyama,et al. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[10] T. Maurer,et al. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[11] D. Greenblatt,et al. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.
[12] R. Austin,et al. A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.
[13] Bruno Boulanger,et al. Towards a new age of virtual ADME/TOX and multidimensional drug discovery , 2004, Molecular Diversity.
[14] D. Greenblatt,et al. In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.
[15] A. Avdeef,et al. pH-Metric logP 10. Determination of Liposomal Membrane-Water Partition Coefficients of lonizable Drugs , 1998, Pharmaceutical Research.
[16] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[17] A. Katz,et al. Comparisons of the interaction of propranolol and timolol with model and biological membrane systems. , 1983, Molecular pharmacology.
[18] T Lavé,et al. Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.
[19] J Brian Houston,et al. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. , 2006, Biochemical pharmacology.
[20] R. Obach,et al. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[21] A. D. Rodrigues,et al. Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.
[22] R. Obach,et al. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[23] Jonas Boström,et al. Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..
[24] D. Greenblatt,et al. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[25] J. Miners,et al. Nonspecific binding of drugs to human liver microsomes. , 2000, British journal of clinical pharmacology.
[26] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[27] M. Wenlock,et al. The Thermodynamics of the Partitioning of Ionizing Molecules Between Aqueous Buffers and Phospholipid Membranes , 2005, Pharmaceutical Research.
[28] J. A. Grant,et al. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..
[29] Jonas Boström,et al. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. , 2003, Journal of molecular graphics & modelling.
[30] J. Miners,et al. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. , 2004, Annual review of pharmacology and toxicology.
[31] Thierry Langer,et al. Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations. , 2006 .